Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2003

View Archived Issues

Neose to develop glycoPEGylated G-CSF

Dual role of adenosine A2A receptor activation in wound healing

CytRx licenses copolymer technologies to SynthRx

Evotec and Roche enter medicinal chemistry collaboration in oncology

SBIR grant supports development of modified annexin V

A novel therapeutic role suggested for vitamin D analogues in breast cancer

PEG-sTNF-RI reported effective in improving the symptoms of rheumatoid arthritis

Good safety profile reported for i.v. LJP-1082 in antiphospholipid syndrome

Potential use of pioglitazone in the treatment of psoriatic arthritis

Beneficial effects described for OPC-28326 in Raynaud's phenomenon

Improved tear production on topical ciclosporin in Sjogren's syndrome

Antiarthritic effects of atlizumab in different patient populations

Betagenon and AstraZeneca team up to tackle type 2 diabetes

Febuxostat in the treatment of gout and hyperuricemia

New TPO receptor agonists and their use as antithrombocytopenic agents

Synthetic discorhabdin analogues and intermediates covered by Sankyo patent

Novel HDAC inhibitors isolated from a marine sponge by Yamanouchi scientists

Steryl sulfatase inhibitors identified by Kyowa Hakko researchers

Sumitomo reports the discovery and testing of naturally produced neuroprotectants

Novel gluconeogenesis inhibitors under study at Sumitomo

Yamanouchi describes new antitumor agents from Pseudomonas species

Bay-43-9006 enters pivotal phase III trial in kidney cancer

Cyberonics submits PMA-S for VNS Therapy

EN-3247 fails to prevent oral mucositis in pivotal trial

Remicade reduces signs and symptoms of anklyosing spondylitis in ASSERT trial

Phase I IND cleared for T-62

Daivobet effective in severe psoriasis

Extended phase II data show RA patients benefit from MabThera for up to 48 weeks

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...